CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.

[1]  R. Fimmers,et al.  Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension , 2013, PloS one.

[2]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[3]  G. Kolios,et al.  CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid , 2013, Clinical and experimental immunology.

[4]  C. Trautwein,et al.  Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes , 2013, Hepatology.

[5]  F. Wong,et al.  Recent advances in our understanding of hepatorenal syndrome , 2012, Nature Reviews Gastroenterology &Hepatology.

[6]  Fabian Kiessling,et al.  Chemokine Cxcl9 attenuates liver fibrosis‐associated angiogenesis in mice , 2012, Hepatology.

[7]  D. Rockey,et al.  Complications of cirrhosis , 2012, Current Opinion in Gastroenterology.

[8]  S. Akira,et al.  CD44 Participates in IP-10 Induction in Cells in Which Hepatitis C Virus RNA Is Replicating, through an Interaction with Toll-Like Receptor 2 and Hyaluronan , 2012, Journal of Virology.

[9]  M. Putt,et al.  Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  R. Stirling,et al.  CXCR3 Expression Elevated on Peripheral CD8(+) Lymphocytes from HIV/HCV Coinfected Individuals. , 2011, Viral immunology.

[11]  T. Sauerbruch,et al.  Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt , 2011, European journal of gastroenterology & hepatology.

[12]  David L. Thomas,et al.  CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. , 2011, The Journal of infectious diseases.

[13]  F. Tacke,et al.  Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[14]  U. Panzer,et al.  CXCR3 Deficiency Exacerbates Liver Disease and Abrogates Tolerance in a Mouse Model of Immune-Mediated Hepatitis , 2011, The Journal of Immunology.

[15]  F. Tacke,et al.  Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection , 2011, Hepatology.

[16]  C. Trautwein,et al.  Functional role of chemokines in liver disease models , 2010, Nature Reviews Gastroenterology &Hepatology.

[17]  J. Pfeilschifter,et al.  CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. , 2010, Journal of autoimmunity.

[18]  M. O. Rocha,et al.  Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[19]  Marianthi Markatou,et al.  Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. , 2009, The Journal of infectious diseases.

[20]  F. Tacke,et al.  Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.

[21]  M. Calvino,et al.  Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. , 2008, World journal of gastroenterology.

[22]  L. Chiriboga,et al.  Intrahepatic levels of CXCR3‐associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C , 2008, Hepatology.

[23]  A. Rieger,et al.  IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV–HCV Coinfection , 2008, Antiviral therapy.

[24]  F. Gao,et al.  CXCL10 regulates liver innate immune response against ischemia and reperfusion injury , 2007, Hepatology.

[25]  K. Tsuneyama,et al.  Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. , 2005, Journal of autoimmunity.

[26]  S. McColl,et al.  Expression of the CXCR3 ligand I‐TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation , 2004, Hepatology.

[27]  Rakesh K. Kumar,et al.  Expression of the chemokine IP‐10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation , 2003, Journal of leukocyte biology.

[28]  C. García-Monzón,et al.  Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease , 2002, American Journal of Gastroenterology.

[29]  F. Marra,et al.  Chemokines in liver inflammation and fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[30]  Xiaodan Ren,et al.  CXC Chemokine Expression After Stimulation with Interferon-&ggr; in Primary Rat Hepatocytes in Culture , 2002, Shock.

[31]  P. Raab,et al.  Hemodynamic Effects of Propranolol and Nitrates in Cirrhotics with Transjugular Intrahepatic Portosystemic Stent-Shunt , 2002, Scandinavian journal of gastroenterology.

[32]  T. Okanoue,et al.  Increase of chemokine interferon‐inducible protein‐10 (IP‐10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes , 2001, Clinical and experimental immunology.

[33]  H. Schild,et al.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study , 2000, Gut.

[34]  J. Cosín,et al.  High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients. , 2012, Cytokine.

[35]  D. Lamarre,et al.  Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients. , 2012, Journal of hepatology.

[36]  Chih-Ping Chen,et al.  Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery , 2003, Annals of Surgical Oncology.

[37]  P. Bioulac-Sage,et al.  [Mechanisms of hepatic fibrogenesis]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[38]  J. Bosch,et al.  Complications of cirrhosis. I. Portal hypertension. , 2000, Journal of hepatology.